1h Free Analyst Time
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 14 molecules. The latest report Integrin Beta 7 - Drugs In Development, 2022, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 5 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Ulcerative Colitis, Pouchitis, Celiac Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS) and Unspecified Gastrointestinal Disorders.
Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
- The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
- AbbVie Inc
- Aviara Pharmaceuticals Inc
- Biora Therapeutics Inc
- C4X Discovery Holdings Plc
- Comera Life Sciences Inc
- DICE Therapeutics Inc
- Genentech USA Inc
- Gilead Sciences Inc
- Morphic Therapeutic Inc
- Polpharma Biologics SA
- Protagonist Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Zealand Pharma AS
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
- ABBV-1882 - Drug Profile
- Product Description
- Mechanism Of Action
- Alpha4 Beta7 Integrin Inhibitor - Drug Profile
- Product Description
- Mechanism Of Action
- etrolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GS-1427 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MORF-057 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Next generation alpha 4 beta 7 selective inhibitors - Drug Profile
- Product Description
- Mechanism Of Action
- Oral alpha 4 beta 7 - Drug Profile
- Product Description
- Mechanism Of Action
- PTG-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Antagonize Integrin Alpha 4 Beta 1 and Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vedolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vedolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- vedolizumab biobetter - Drug Profile
- Product Description
- Mechanism Of Action
- vedolizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ZP-10000 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
- Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AbbVie Inc, 2022
- Pipeline by Aviara Pharmaceuticals Inc, 2022
- Pipeline by Biora Therapeutics Inc, 2022
- Pipeline by C4X Discovery Holdings Plc, 2022
- Pipeline by Comera Life Sciences Inc, 2022
- Pipeline by DICE Therapeutics Inc, 2022
- Pipeline by Genentech USA Inc, 2022
- Pipeline by Gilead Sciences Inc, 2022
- Pipeline by Morphic Therapeutic Inc, 2022
- Pipeline by Polpharma Biologics SA, 2022
- Pipeline by Protagonist Therapeutics Inc, 2022
- Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Pipeline by Zealand Pharma AS, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by outes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Aviara Pharmaceuticals Inc
- Biora Therapeutics Inc
- C4X Discovery Holdings Plc
- Comera Life Sciences Inc
- DICE Therapeutics Inc
- Genentech USA Inc
- Gilead Sciences Inc
- Morphic Therapeutic Inc
- Polpharma Biologics SA
- Protagonist Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Zealand Pharma AS
